Your browser doesn't support javascript.
loading
What next after GDP-based cost-effectiveness thresholds?
Chi, Y-Ling; Blecher, Mark; Chalkidou, Kalipso; Culyer, Anthony; Claxton, Karl; Edoka, Ijeoma; Glassman, Amanda; Kreif, Noemi; Jones, Iain; Mirelman, Andrew J; Nadjib, Mardiati; Morton, Alec; Norheim, Ole Frithjof; Ochalek, Jessica; Prinja, Shankar; Ruiz, Francis; Teerawattananon, Yot; Vassall, Anna; Winch, Alexander.
Afiliação
  • Chi YL; Center for Global Development, London, SW1P 3SE, UK.
  • Blecher M; National Treasury, Pretoria, 0002, South Africa.
  • Chalkidou K; Center for Global Development, London, SW1P 3SE, UK.
  • Culyer A; Department of Infectious Disease Epidemiology, Imperial College London, London, SW7 2AZ, UK.
  • Claxton K; Centre for Health Economics, Department of Economics and Related Studies, University of York, York, YO10 5DD, UK.
  • Edoka I; Centre for Health Economics, Department of Economics and Related Studies, University of York, York, YO10 5DD, UK.
  • Glassman A; School of Public Health, Wits University, Parktown, 2193, South Africa.
  • Kreif N; Center for Global Development, Washington, D.C., 20036, USA.
  • Jones I; Centre for Health Economics, Department of Economics and Related Studies, University of York, York, YO10 5DD, UK.
  • Mirelman AJ; Sightsavers, Haywards Health, RH16 3BW, UK.
  • Nadjib M; Centre for Health Economics, Department of Economics and Related Studies, University of York, York, YO10 5DD, UK.
  • Morton A; Faculty of Public Health, Department of Health Policy and Administration, Universitas Indonesia, Depok, Indonesia.
  • Norheim OF; University of Glasgow, Glasgow, UK.
  • Ochalek J; BCEPS, Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.
  • Prinja S; Centre for Health Economics, Department of Economics and Related Studies, University of York, York, YO10 5DD, UK.
  • Ruiz F; Department of Community Medicine & School of Public Health, Post Graduate Institute of Medical Education and Research, Chandigarh, 160 012, India.
  • Teerawattananon Y; Center for Global Development, London, SW1P 3SE, UK.
  • Vassall A; Department of Infectious Disease Epidemiology, Imperial College London, London, SW7 2AZ, UK.
  • Winch A; Health Intervention and Technology Assessment Program, Ministry of Public Health, Thailand, Nonthaburi, 11000, Thailand.
Gates Open Res ; 4: 176, 2020.
Article em En | MEDLINE | ID: mdl-33575544
ABSTRACT
Public payers around the world are increasingly using cost-effectiveness thresholds (CETs) to assess the value-for-money of an intervention and make coverage decisions. However, there is still much confusion about the meaning and uses of the CET, how it should be calculated, and what constitutes an adequate evidence base for its formulation. One widely referenced and used threshold in the last decade has been the 1-3 GDP per capita, which is often attributed to the Commission on Macroeconomics and  WHO guidelines on Choosing Interventions that are Cost Effective (WHO-CHOICE). For many reasons, however, this threshold has been widely criticised; which has led experts across the world, including the WHO, to discourage its use. This has left a vacuum for policy-makers and technical staff at a time when countries are wanting to move towards Universal Health Coverage . This article seeks to address this gap by offering five practical options for decision-makers in low- and middle-income countries that can be used instead of the 1-3 GDP rule, to combine existing evidence with fair decision-rules or develop locally relevant CETs. It builds on existing literature as well as an engagement with a group of experts and decision-makers working in low, middle and high income countries.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Guideline / Health_economic_evaluation Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Guideline / Health_economic_evaluation Idioma: En Ano de publicação: 2020 Tipo de documento: Article